Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 10/20 | 0.71 |
| ▸ | HTR7 | P34969 | 5/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 6/20 | 0.50 |
| ▸ | HTR3B | O95264 | 6/20 | 0.50 |
| ▸ | HTR3A | P46098 | 6/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 6/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 6/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 5/20 | 0.49 |
| ▸ | HTR1D | P28221 | 2/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238705 | 0.94 | ADRB1 (0.63) | ADRB1HTR7HTR3EHTR3BHTR3A | |
| SCHEMBL1022323 | 0.86 | ADRB1 (0.71) | ADRB1HTR7HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL9743067 | 0.84 | ADRB1 (0.69) | ADRB1HTR7HTR3EHTR3BHTR3A | |
| SCHEMBL12583478 | 0.83 | ADRB1 (0.47) | ADRB1ALDH1A1HTTMAPT | |
| SCHEMBL19998610 | 0.83 | HPGD (0.47) | ADRB1ALDH1A1TP53HTTMAPT | |
| SCHEMBL221254 | 0.83 | ADRB1 (1.00) | ADRB1HTR7HTR3EHTR3BHTR3A | |
| SCHEMBL478208 | 0.83 | ADRB1 (0.57) | ADRB1HTR7HTR3EHTR3BHTR3A | |
| SCHEMBL10151434 | 0.81 | HPGD (0.50) | ADRB1ALDH1A1THRBTP53HTT | |
| SCHEMBL9881498 | 0.81 | HPGD (0.50) | ADRB1ALDH1A1THRBTP53HTT | |
| Hydrochloric Acid SCHEMBL8318106 | 0.81 | ADRB1 (0.55) | ADRB1HTR7HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020210377-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210383-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-1189903-B1 | NOVEL BENZO[F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-28 | — | — | EP | disclosed |
| US-6566362-B2 | Use as topical antibiotics | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2002-09-26 | — | — | US | disclosed |
| EP-1189903-A1 | NOVEL BENZO F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001002396-A1 | NOVEL BENZO[F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | KCNQ2, KCNQ1, KCNQ4 | ADRB1 469/4885HTR7 1237/4885HTR3E 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.